Global arthralgia market to reach $8.25B by 2030 at 7.9% CAGR

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Arthralgia Market Projected To Reach By 2030?

The arthralgia market size has experienced robust growth in recent years. It is forecast to grow from $5.62 billion in 2025 to $6.09 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.2%. This historical expansion can be attributed to the rising prevalence of joint-related disorders, an aging global demographic, increasing awareness of musculoskeletal health, the broadening availability of pharmaceutical pain management options, and the development of outpatient orthopedic care.

The arthralgia market is projected to undergo significant growth in the upcoming years. Its size is expected to escalate to $8.26 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.9%. This growth during the forecast period can be attributed to an escalating demand for personalized treatment approaches, an increase in the adoption of biologic and targeted therapies, the expansion of home-based solutions for pain management, a greater emphasis on long-term symptom control, and increased investments in research related to joint health. Key trends during the forecast period include the rising acceptance of personalized pain management therapies, an increase in the use of combination treatment strategies, a growing focus on the early diagnosis of joint disorders, the expansion of non-invasive pain relief options, and enhanced patient-centered treatment models.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/arthralgia-global-market-report

Which Important Drivers Are Guiding The Arthralgia Market Growth?

A projected increase in rheumatoid arthritis occurrences is anticipated to drive expansion in the arthralgia market. This chronic autoimmune condition primarily targets joints, leading to inflammation, discomfort, and potential structural harm. Factors contributing to the rising incidence of rheumatoid arthritis include an aging populace, genetic susceptibility, evolving lifestyles, and environmental elements such as smoking and pollution. Rheumatoid arthritis (RA) induces arthralgia through the initiation of persistent joint inflammation, resulting in pain, rigidity, and escalating deterioration. As an illustration, data from Arthritis Australia, an Australia-based non-profit organization, reported in February 2024, predicts that by 2040, arthritis cases in Australia will climb to 5.39 million from 4.11 million in 2025. Within this, osteoarthritis is projected to grow to 3.11 million from 2.35 million, and rheumatoid arthritis cases are anticipated to reach 748,721. Consequently, the escalating prevalence of rheumatoid arthritis is fueling the expansion of the arthralgia market.

What Are The Different Segment Types In The Arthralgia Market Segment Breakdown?

The arthralgia market covered in this report is segmented –

1) By Cause: Osteoarthritis, Rheumatoid Arthritis, Gout, Psoriatic Arthritis, Lupus, Injuries, Infections, Other Causes

2) By Treatment Type: Medications, Therapies, Surgical Interventions, Lifestyle And Home Remedies

3) By Route Of Administration: Oral, Injectable, Topical, Transdermal

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospital, Clinics, Homecare Settings, Rehabilitation Centers

Subsegments:

1) By Osteoarthritis: Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, Spine Osteoarthritis, Shoulder Osteoarthritis

2) By Rheumatoid Arthritis: Seropositive Rheumatoid Arthritis, Seronegative Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Early-Onset Rheumatoid Arthritis

3) By Gout: Primary Gout, Secondary Gout, Gouty Arthritis

4) By Psoriatic Arthritis: Symmetric Psoriatic Arthritis, Asymmetric Psoriatic Arthritis, Psoriatic Spondylitis, Distal Interphalangeal Predominant Psoriatic Arthritis

5) By Lupus: Systemic Lupus Erythematosus (SLE), Discoid Lupus Erythematosus, Drug-induced Lupus, Neonatal Lupus

6) By Injuries: Sports-related Injuries, Trauma and Fractures, Sprains and Strains, Tendon or Ligament Damage

7) By Infections: Septic Arthritis, Viral Arthritis, Bacterial Infections, Fungal Infections

8) By Other Causes: Fibromyalgia, Overuse Injuries, Sarcoidosis, Ankylosing Spondylitis, Crystal-induced Arthritis

What Trends Are Influencing The Evolution Of The Arthralgia Market?

Leading companies operating within the arthralgia market are concentrating on developing innovative treatments, such as RMAT-designated gene therapy, to offer patients advanced solutions that provide long-term pain relief and improved joint function. RMAT-designated gene therapy refers to a treatment that has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, which serves to expedite the development and review process for innovative gene therapies addressing serious or life-threatening conditions. For instance, in March 2024, Pacira BioSciences Inc., a US-based pharmaceutical company, was granted Regenerative Medicine Advanced Therapy (RMAT) designation for its product PCRX-201 (enekinragene inzadenovec) by the U.S. Food and Drug Administration (FDA). This product is an innovative, intra-articular gene therapy candidate that utilizes a helper-dependent adenovirus (HDAd) for treating knee osteoarthritis. The therapy is engineered to produce interleukin-1 receptor antagonists (IL-1Ra). Pacira expressed its satisfaction in being awarded the FDA’s inaugural RMAT designation for a gene therapy specifically targeting osteoarthritis and underscored the promising preliminary clinical results, which suggest that PCRX-201 has the potential to be a disease-modifying treatment.

Who Are The Well-Known Companies In The Arthralgia Market?

Major companies operating in the arthralgia market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., UCB S.A., Hikma Pharmaceuticals PLC, Ferring Pharmaceuticals, KD Pharma Group S.A., SI-BONE Inc., Xalud Therapeutics Inc., Incannex Healthcare Limited, Cytonics Corporation

Get The Full Arthralgia Market Report:

https://www.thebusinessresearchcompany.com/report/arthralgia-global-market-report

Which Region Leads The Arthralgia Market In Overall Market Size?

North America was the largest region in the arthralgia market in 2025. The regions covered in the arthralgia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Arthralgia Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/arthralgia-global-market-report

Browse Through More Reports Similar to the Global Arthralgia Market 2026, By The Business Research Company

Lenalidomide Market Report 2026

https://www.thebusinessresearchcompany.com/report/lenalidomide-global-market-report

Anthracite Market Report 2026

https://www.thebusinessresearchcompany.com/report/anthracite-global-market-report

Artichokes Market Report 2026

https://www.thebusinessresearchcompany.com/report/artichokes-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795